Cargando…
Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study
BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 pa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758869/ https://www.ncbi.nlm.nih.gov/pubmed/33425023 http://dx.doi.org/10.1177/1758835920975603 |
_version_ | 1783627016386379776 |
---|---|
author | Zhang, Hanwen Zhang, Ning Li, Yaming Liang, Yiran Yang, Qifeng |
author_facet | Zhang, Hanwen Zhang, Ning Li, Yaming Liang, Yiran Yang, Qifeng |
author_sort | Zhang, Hanwen |
collection | PubMed |
description | BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 patients with mucinous carcinoma from 1994 to 2014 were identified. Clinicopathological characteristics were compared using the chi-square test. BCSS curves were generated using the Kaplan–Meier method. The prognostic significance of all demographic and clinicopathological characteristics and treatment patterns were calculated using univariate and multivariate regression analyses. RESULTS: Mucinous carcinoma was demonstrated to be less aggressive than invasive ductal carcinoma and predicted a better prognosis in the Kaplan–Meier analysis (hazard ratios = 0.336, 95% confidence interval: 0.308–0.368, p < 0.001). Univariate and multivariate analyses revealed that chemotherapy did not provide any additional benefit for patients with mucinous carcinoma. Predictors for receiving chemotherapy were younger age, estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-positive status, higher grade, larger tumor size, lymph node involvement, radiation reception, and mastectomy. Further subgroup analysis verified that regardless of the hormone receptor (HR) and lymph node (LN) status, patients did not benefit from chemotherapy. CONCLUSION: Our study showed that patients with HR+/LN– mucinous carcinoma did not benefit from chemotherapy and that chemotherapy could not improve the survival of all subtypes of mucinous carcinoma based on large-scale SEER data. These results support that patients with mucinous carcinoma could be exempt from chemotherapy. Additional research is needed to further evaluate the impact of adjuvant treatments, particularly in patients with favorable histology. |
format | Online Article Text |
id | pubmed-7758869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77588692021-01-08 Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study Zhang, Hanwen Zhang, Ning Li, Yaming Liang, Yiran Yang, Qifeng Ther Adv Med Oncol Original Research BACKGROUND: In this study, we investigated the impact of chemotherapy on breast cancer-specific survival (BCSS) in patients with mucinous carcinoma using the surveillance, epidemiology, and end results (SEER) database. METHODS: A large-scale SEER-based retrospective analysis was conducted; 13,329 patients with mucinous carcinoma from 1994 to 2014 were identified. Clinicopathological characteristics were compared using the chi-square test. BCSS curves were generated using the Kaplan–Meier method. The prognostic significance of all demographic and clinicopathological characteristics and treatment patterns were calculated using univariate and multivariate regression analyses. RESULTS: Mucinous carcinoma was demonstrated to be less aggressive than invasive ductal carcinoma and predicted a better prognosis in the Kaplan–Meier analysis (hazard ratios = 0.336, 95% confidence interval: 0.308–0.368, p < 0.001). Univariate and multivariate analyses revealed that chemotherapy did not provide any additional benefit for patients with mucinous carcinoma. Predictors for receiving chemotherapy were younger age, estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-positive status, higher grade, larger tumor size, lymph node involvement, radiation reception, and mastectomy. Further subgroup analysis verified that regardless of the hormone receptor (HR) and lymph node (LN) status, patients did not benefit from chemotherapy. CONCLUSION: Our study showed that patients with HR+/LN– mucinous carcinoma did not benefit from chemotherapy and that chemotherapy could not improve the survival of all subtypes of mucinous carcinoma based on large-scale SEER data. These results support that patients with mucinous carcinoma could be exempt from chemotherapy. Additional research is needed to further evaluate the impact of adjuvant treatments, particularly in patients with favorable histology. SAGE Publications 2020-12-18 /pmc/articles/PMC7758869/ /pubmed/33425023 http://dx.doi.org/10.1177/1758835920975603 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Zhang, Hanwen Zhang, Ning Li, Yaming Liang, Yiran Yang, Qifeng Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title_full | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title_fullStr | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title_full_unstemmed | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title_short | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
title_sort | evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758869/ https://www.ncbi.nlm.nih.gov/pubmed/33425023 http://dx.doi.org/10.1177/1758835920975603 |
work_keys_str_mv | AT zhanghanwen evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy AT zhangning evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy AT liyaming evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy AT liangyiran evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy AT yangqifeng evaluationofefficacyofchemotherapyformucinouscarcinomaasurveillanceepidemiologyandendresultscohortstudy |